Singapore, April 3 -- Japanese pharmaceutical company Shionogi & Co. has entered into an exclusive licensing agreement with Link Medical Products, part of Clinigen, the global specialty pharmaceutical services group, for the development and commercialisation of cefiderocol in Australia and New Zealand.

The Therapeutic Goods Administration (TGA) regulatory authority in Australia accepted the market authorisation application for cefiderocol and the application is under evaluation.

Under the terms of the agreement, Link will in-license cefiderocol from Shionogi and obtain exclusive rights for its development and commercialization in Australia and New Zealand. Shionogi will receive an upfront payment, milestone payments based on development...